From Supertankers To Speedboats: Executives Make The Leap From Big Pharma To Start-Ups
Trade-Offs Include Faster Decision-Making, Greater Risk-Taking
Executive Summary
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.